Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 13s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Recent Advances in Analytical Method Development and Validation for Simultaneous Estimation of Atorvastatin and Etoricoxib Using UV-Vis Spectrophotometry: A Comprehensive Review

Puja Gulati[*1], Tania Bhagat[1]

[*1]Professor & Principal, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab.

Email ID: Puja_duggal@yahoo.co.in

[1]Research Scholar, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab.

Email ID: taniabhagat001911@gmail.com

***Corresponding Author:**

Puja Gulati

Email ID: Puja_duggal@yahoo.co.in

Cite this paper as: Puja Gulati, Tania Bhagat, (2025) Recent Advances in Analytical Method Development and Validation for Simultaneous Estimation of Atorvastatin and Etoricoxib Using UV-Vis Spectrophotometry: A Comprehensive Review. *Journal of Neonatal Surgery*, 14 (13s), 200-214.

ABSTRACT

UV-Vis spectrophotometry functions as a popular analytical technique that pharmaceutical analysis adopts intensively for API quantity determination and formulation quality monitoring. This examination explores the application of UV-Vis spectrophotometry to simultaneously determine atorvastatin and etoricoxib which are pharmaceutical agents used in cardiovascular disease and inflammatory disorder treatment. Molecules inside complex mixtures can be measured using the absorption technique because the technique enables absorption of specific light wavelengths. Spectral wavelength overlaps create interference with excipients elements along with introducing matrix interferents thus posing difficulties to simultaneous estimation methods. A combination of derivative spectrophotometry techniques with both multivariate calibration and chemometric methods enhances the accuracy and sensitivity and precision of UV-Vis spectrophotometry measurements. The latest advancements in simultaneous analysis of atorvastatin along with etoricoxib in complicated pharmaceutical materials and biological specimens create precise and controlled determination methods. The advancement of UV-Vis spectrophotometry through research resulted in portable device and microfluidic system creation which enabled extended on-site analysis capabilities together with point-of-care testing potential. The review details the operation of this method throughout pharmaceutical quality controls and stability testing and bioequivalence examinations and bioanalytical work focused toward pharmaceutical product protection. Future developments in UV-Vis spectrophotometry will focus on improving detection sensitivity together with lowering interferences and enhancing mobility as part of green chemical methods and standardized analytical procedures worldwide. The future development agenda aims to strengthen UV-Vis spectrophotometry as an indispensable pharmaceutical analytical instrument.

Keywords: *UV-Vis spectrophotometry, atorvastatin, etoricoxib, simultaneous estimation, pharmaceutical analysis, multivariate calibration*

GRAPHICAL ABSTRACT



UV-Vis spectrophotometry methods serve for combined atorvastatin and etoricoxib determinations as described in the figure. The figure displays information about method development strategies while showing validation methodologies together with recent breakthroughs and encountered challenges.

1. INTRODUCTION

The pharmacological agents atorvastatin and etoricoxib have different therapeutic functions but prove essential in different medical situations. Atorvastatin functions as a commonly prescribed drug which belongs to the statin class for treating both hyperlipidemia and cardiovascular diseases.(1) Atorvastatin hinders HMG-CoA reductase to synthesize cholesterol which decreases LDL cholesterol concentrations and protects patients from heart attacks and strokes and other cardiovascular conditions. (2) Both drugs serve different purposes because Etoricoxib targets cyclooxygenase-2 (COX-2) to manage pain alongside inflammation and fever reduction. Medical professionals use this prescription to treat patients with osteoarthritis, rheumatoid arthritis and people experiencing gout-related acute pain or inflammation-based medical disorders.(3) The dual determination of atorvastatin and etoricoxib plays a vital role in pharmaceutical analysis because medical professionals treat common diseases affecting elderly patients through sustained medicine administration. Medical practitioners frequently provide their patients with both drugs because patients commonly have cardiovascular diseases and inflammatory disorders simultaneously.(4, 5) Therapeutic drug monitoring depends on accurate plasma or serum sample analysis methods to optimize drug performance and reduce adverse side effects. The ability to measure atorvastatin and etoricoxib at once serves to confirm proper patient medication doses which minimizes drug conflicts and enhances the combined treatment of their health issues. Therapeutic drug monitoring depends on accurate plasma or serum sample analysis methods to optimize drug performance and reduce adverse side effects. The ability to measure atorvastatin and etoricoxib at once serves to confirm proper patient medication doses which minimizes drug conflicts and enhances the combined treatment of their health issues. (6) Product safety and efficacy standards along with correct active ingredient amounts in pharmaceutical drug items verify through quality control tests which are essential for the pharmaceutical industry. Therapeutic and toxic levels can be safeguarded when administering atorvastatin together with etoricoxib using combination therapy through the need for simultaneous estimation of drug concentrations.(7) The analysis of such drug combinations requires specially designed assessment techniques to differentiate between close-structured drugs. The task of measuring these drugs becomes complicated because atorvastatin and etoricoxib show different absorption behaviors and molecular characteristics. (8) A method which conducts simultaneous estimation of these two drugs will reduce both costs and analysis time by removing the requirement for independent examination steps that would otherwise prolong pharmaceutical product release. These research methods must assess drug body behavior by tracking their absorption along with distribution and metabolism and excretion processes. (9) Drug bioavailability responds to multiple variables including drug-drug interactions because these phenomena modify the safety profile as well as therapeutic effectiveness of medical regimens. (10) Academics along with medical professionals benefit from research methods that determine both atorvastatin and etoricoxib concurrently because these techniques help identify inter-drug responses when used in combination compared to solitary treatment. Optimal drug dosing requires vital information about therapeutic effectiveness and adverse effect risks for designing the best treatment regimens. (11) Polypharmacy creates a typical clinical problem in these situations so scientists must develop testing methods that precisely measure multiple drugs from one sample. The clinical need exists for efficient analysis methods of atorvastatin and etoricoxib with other pharmaceutical compounds because these techniques assist doctors in tracking patient medication compliance and adjustment of prescribed dosages. (12) Device accuracy increases through UV-Vis spectrophotometry in drug level measurement because the method offers inexpensive operation linked to its dependable and straightforward functionality. The test examines how light gets absorbed by a sample across various wavelengths to detect exact compound amounts through their distinct absorption signature. UV-Vis spectrophotometry provides beneficial characteristics during the concurrent measurement of atorvastatin and etoricoxib.(13) It provides laboratories with a useful tool to detect both drugs simultaneously without demanding complicated laboratory preparation steps thus making it suitable for normal laboratory work in research areas and clinical settings. The use of proper multi-component analysis methods enables UV-Vis spectrophotometry to achieve both high sensitivity and specificity for analysis. UV-Vis spectrophotometry maintains a crucial position in pharmaceutical and biological sample analysis to guarantee accurate simultaneous quantification of atorvastatin and etoricoxib. (14) (15) Medical practice requires reliable methods for biological matrix tramonitoring of both atorvastatin and etoricoxib together since they are frequently prescribed in combination. The efficient development of methods to measure both drugs at once using UV-Vis spectrophotometry enables improved drug quality control practices as well as better patient safety outcomes and therapeutic results. Future developments in analytical methods represent an essential requirement because they fulfill increasing pharmaceutical sector and medical system needs.(16) (17)

2. FUNDAMENTALS OF UV-VIS SPECTROPHOTOMETRY

Analytics employ UV-Vis spectrophotometry as a common method to assess light absorption within UV and visible wavelengths by test samples. The methodology functions through the mechanism where molecules show absorption at wavelengths which match their electronic transition points. The absorbance of electromagnetic light between 200 to 800 nm wavelengths reveals essential data about solution composition and molecular structure of analyzed substances.(18)

Principle of UV-Vis Spectrophotometry

UV-Vis spectrophotometry functions on the basis that electromagnetic radiation interacts with different types of matter. Antennae containing UV or visible light rays encounter samples where some wavelengths absorb the molecules but permit others to pass through. When light passes through a solution the molecules absorb specific frequencies that promote electron transitions from lower to higher energy states. A sample's concentration of absorbing species defines the absorption level at specific wavelengths through Beer-Lambert's law.(19, 20)

Beer-Lambert's law, also known as Beer's law, is the foundation of UV-Vis spectrophotometry and is expressed as:

$A=\varepsilon \cdot c \cdot l$

Where:

- A is the absorbance of the sample,
- ε is the molar absorptivity (or molar absorption coefficient),
- c is the concentration of the analyte,
- l is the path length through the sample.

UV-Vis spectrophotometry functions on the basis that electromagnetic radiation interacts with different types of matter. Antennae containing UV or visible light rays encounter samples where some wavelengths absorb the molecules but permit others to pass through. When light passes through a solution the molecules absorb specific frequencies that promote electron transitions from lower to higher energy states. A sample's concentration of absorbing species defines the absorption level at specific wavelengths through Beer-Lambert's law.(21)

Applications in Pharmaceutical Analysis

UV-Vis spectrophotometry functions on the basis that electromagnetic radiation interacts with different types of matter. Antennae containing UV or visible light rays encounter samples where some wavelengths absorb the molecules but permit others to pass through. When light passes through a solution the molecules absorb specific frequencies that promote electron transitions from lower to higher energy states. A sample's concentration of absorbing species defines the absorption level at specific wavelengths through Beer-Lambert's law. (22)

1. **Quantification of Active Pharmaceutical Ingredients (APIs)**: UV-Vis spectrophotometry functions on the basis that electromagnetic radiation interacts with different types of matter. Antennae containing UV or visible light rays encounter samples where some wavelengths absorb the molecules but permit others to pass through. When light passes through a solution the molecules absorb specific frequencies that promote electron transitions from lower to higher energy states. A sample's concentration of absorbing species defines the absorption level at specific wavelengths through Beer-Lambert's law.(23)
2. **Drug Stability Studies**: UV-Vis spectrophotometry functions on the basis that electromagnetic radiation interacts with different types of matter. Antennae containing UV or visible light rays encounter samples where some wavelengths absorb the molecules but permit others to pass through. When light passes through a solution the molecules absorb specific frequencies that promote electron transitions from lower to higher energy states. A sample's concentration of absorbing species defines the absorption level at specific wavelengths through Beer-Lambert's law.(24)
3. **Formulation Development**: UV-Vis spectrophotometry functions on the basis that electromagnetic radiation interacts with different types of matter. Antennae containing UV or visible light rays encounter samples where some wavelengths absorb the molecules but permit others to pass through. When light passes through a solution the molecules absorb specific frequencies that promote electron transitions from lower to higher energy states. A sample's concentration of absorbing species defines the absorption level at specific wavelengths through Beer-Lambert's law.(25)
4. **Analysis of Drug Release**: UV-Vis spectrophotometry enables dissolution testing for analyzing how drugs are released from dosage forms while measuring their profiles. The technique enables detection of drug concentration changes in the dissolution medium throughout time for providing essential information about drug release kinetics and pharmaceutical availability. The controlled-release formulation development requires precise drug release rate management therefore this becomes essential for the process. (26)
5. **Identification of Impurities and Contaminants**: UV-Vis spectrophotometry functions as a method for both recognizing impurities along with measuring their concentration in pharmaceutical products. A detection method used by UV-Vis spectrophotometry involves analyzing absorption patterns between a drug substance and reference standard to identify unwanted substances or degradation products. Pharmacological products require the technique to fulfill regulatory criteria for both purity and safety standards.(27)

6. **Bioanalytical Applications**: The analysis of drug concentrations within biological samples such as plasma and serum and urine makes use of UV-Vis spectrophotometry in clinical laboratories. The method proves essential when performing therapeutic drug monitoring because it provides accurate readings of medication concentrations to ensure both safety and effectiveness. UV-Vis spectrophotometry serves analytical purposes in biopharmaceutical research for monitoring drug ADME processes and drug distribution throughout the body.(28)
7. **Simultaneous Estimation of Drug Combinations**: UV-Vis spectrophotometry provides vital performance in quantifying several drugs that combine within therapeutic regimens. UV-Vis spectrophotometry measures both atorvastatin and etoricoxib drugs precisely in combined therapies with a single analysis. The mixture of multi-component analysis methods including derivative spectroscopy and multivariate calibration lets researchers measure drug amounts without getting affected by other mixture components. (29)

3. ANALYTICAL METHOD DEVELOPMENT

Method development practices in pharmaceutical analysis serve as a vital element because they secure precise and reliable as well as efficient approaches to quantitate active pharmaceutical ingredient (API) concentrations. The approach for estimating atorvastatin and etoricoxib at the same time requires selecting proper wavelengths and optimizing the method before making calibration curves for measuring linearity. A laboratory method should be developed which achieves regulatory certification along with practical utility for pharmaceutical quality control laboratories and clinical applications.(30)

Selection of Wavelengths for Atorvastatin and Etoricoxib

The correct identification of analysis wavelengths stands as a vital element for successful UV-Vis spectrophotometry analysis of both atorvastatin and etoricoxib compounds. The maximum absorbance points for atorvastatin and etoricoxib require specific wavelength selection because these represent the best combination for measuring their concentrations with accuracy. The selection of this wavelength is optimal because atorvastatin demonstrates its strongest absorption peak and other compounds in mixtures do not create interferences. (31) Etoricoxib shows its maximum absorption at 231 nm unlike the different wavelength at which a selective COX-2 inhibitor operates. Due to their separate absorption maxima these compounds can be evaluated simultaneously through UV-Vis spectrophotometry. (32) A method for simultaneous analysis development requires careful evaluation of spectral overlap because it becomes relevant when the compounds appear together in mixtures. A solution for this problem consists of choosing wavelengths which support the significant absorption of both compounds yet maintain distinct peaks. The implementations of derivative spectrophotometry and multi-wavelength techniques become necessary for cases involving required peak separation. (33)The wavelength selection process needs to consider the concentration ranges of atorvastatin and etoricoxib in biological samples or pharmaceutical formulations to ensure proper instrument detection.(34)



Figure 1: A diagram illustrates the individual absorption peaks of both atorvastatin (246 nm) and etoricoxib (231 nm) compounds. A graphical representation supports the related discussion about wavelength selection for simultaneous estimates in this section.

Method Optimization Strategies

After picking appropriate wavelengths for atorvastatin and etoricoxib the method optimization phase starts. Method optimization requires fine adjustment of different parameters which enhances both sensitivity and analytic accuracy and precision levels. The refinement of analytical procedures contains three main components: solvent selection and maintenance of pH values during analysis and development of appropriate sample handling methods.(35)

1. **Solvent Selection**: The selection of solvent for drug sample dissolution needs to preserve the absorption behavior of atorvastatin together with etoricoxib. The UV-Vis spectrophotometry requires common solutions like methanol, ethanol, acetonitrle and phosphate buffer solutions for its operations. A solvent which dissolves the drugs adequately should demonstrate low absorption strength at the chosen wavelength wavelengths. The combination of suitable solvents enables maximum drug dissolution when used together without compromising the light-absorption behavior of the pharmaceutical compounds.(36)
2. **pH Optimization**: A drug's absorption spectra will significantly change based on the pH value adopted in solvent or buffer solutions. The optimization of atorvastatin's absorption measurement requires determination of the solution pH range because high or low pH values can affect both compounds' absorption spectra. (37)The choice of phosphate buffer solution requires a pH value between neutral and slightly acidic for optimal results although drug-specific chemical factors might necessitate alternative conditions.(38)
3. **Sample Preparation**: Accurate and reliable outcomes require proper preparation of samples. Drugs require a solvent for dissolving before filtration through a particle-filtering device. Sample dilution might become essential before performing measurements with the UV-Vis spectrophotometer because the absorbance values must lie within its linear operating range. The dilution method prevents measurement errors in instruments when absorbance levels are too high.(39)
4. **Temperature Control**: The spectra absorption behavior of particular compounds depends on temperature measurements. For reliable results during UV-Vis spectrophotometry analysis scientists must keep temperatures at a constant level. The drug solubility suffers effects from temperature fluctuations which produce alterations in the measured absorbance values.(40)
5. **Interference Minimization**: The analysis of mixtures demands proper control of interfering substances which include both pharmaceutical excipients and impurities that exist in pharmaceutical formulations. The analysis benefits from two solution methods which use proper wavelength selection alongside derivative spectrophotometry and multivariate analysis and other combined techniques to handle overlapping spectra.(41) (42)

Calibration Curves and Linearity

Standard calibration curve creation follows optimization to discover the relationship between atorvastatin-etrocoxib concentrations and absorbance levels. Standard solutions consisting of known drug concentrations are used for plotting calibration curves which show a relationship between absorbance reading and drug concentrations.(43) A curve is developed through atorvastatin and etoricoxib standard solutions which allows researchers to determine unknown sample concentrations by measuring their absorbance values. The experimental system measures the absorbance of standard solutions at chosen wavelengths before generating linear plots from the acquired data. An ideal calibration curve will demonstrate a direct correlation between absorbance measurements and concentration values. The linear regression-derived equation enables calculating unknown atorvastatin and etoricoxib concentrations through the calibration curve method.(44) Linearity plays a vital role in developing calibration curves. Reliability in this method requires absorbance to display a direct proportion between drug concentration across different ranges of drug amounts. Measuring solutions having different concentration levels enables instrument reading within its linear operating range.(45) A nonlinear curve suggests problems in preparation techniques and instrumental calibration and the choice of solvent. The method demonstrates accuracy for measuring atorvastatin and etoricoxib concentrations in pharmaceutical and biological samples because of its good linear relationship.(46)

4. VALIDATION OF ANALYTICAL METHODS

An analytical method validation serves as an essential step to verify that it satisfies all necessary performance requirements for specific applications. Pharmaceutical analysis requires validation to confirm analytical techniques deliver reliable and accurate results with high reproducibility for official approval purposes. The validation process involves conducting assessments on performance parameters that include accuracy and precision with addition of specificity and sensitivity as well as linearity and range and robustness and ruggedness. The method's suitability for utilizing UV-Vis spectrophotometry to estimate atorvastatin and etoricoxib depends on these essential parameters.(47)

Validation Parameters

1. **Accuracy**: Accuracy refers to the closeness of the measured value to the true value or the reference standard. The measurement quality reveals itself through this parameter because the method represents the actual concentration of the analyte in the sample. The accuracy evaluation for atorvastatin and etoricoxib simultaneous determination happens through reference method validation or drug concentrations known standard assessments. The calculation of accuracy uses percentage recovery values which result from comparing the analytical findings with the reference values.(48)
2. **Precision**: The precision of a method describes its consistency regarding duplicate measurements conducted under

equivalent settings. The methods of precision exist in three separate classifications.(49)

- **Repeatability**: The precision of a method describes its consistency regarding duplicate measurements conducted under equivalent settings. The methods of precision exist in three separate classifications.(50)
- **Intermediate Precision**: The analysis is performed precisely each time it is conducted by different analysts when using the same equipment and method across different days. The analysis is performed precisely each time it is conducted by different analysts when using the same equipment and method across different days.(51)
- **Reproducibility**: The measurement precision indicates the consistency of test results when the procedures take place with varied equipment or operation across multiple laboratories. The reliability of measurements made on atorvastatin and etoricoxib can be determined through repeated analyses of a single sample and calculation of standard deviation and relative standard deviation (RSD). High precision appears when RSD measures show low values in the analysis.(52)

3. **Specificity**: The method must excel at determining target compounds (atorvastatin or etoricoxib) while present among other components found in the sample including excipients and sample impurities or degradation products. The determination of specificity is essential in simultaneous estimation because other sample components might produce inaccurate measurements. To assess specificity researchers need to run tests with interfering substances present while they check for separate absorption peaks for each drug in the sample.(53)
4. **Sensitivity**: A technique demonstrates high sensitivity when it detects low quantities of the substance analyzed in samples. The detection capability and quantification capabilities of a method are commonly assessed through their LOD and LOQ values. Such a method demonstrates outstanding detection capabilities which enable measurement of atorvastatin and etoricoxib concentrations present in very small amounts thereby benefiting bioanalytical work with scarce drug samples.(54)
5. **Linearity**: Linearity exists when laboratory methods return directly related results supported by the analyte concentration within a specific measurement area. The validation of analytical methods through linearity checking involves testing standard solutions containing different atorvastatin and etoricoxib concentrations while measuring their absorbance against concentration. (55)The method shows adequate quantification capacity for drugs because it establishes direct links between drug concentration levels across the complete measurement range. The assessment of this parameter guarantees method performance acceptance because it determines the ability to accurately measure drug concentration across different dosage strengths.(56)
6. **Range**: A method determines its measurement capabilities by spanning concentrations from highest to lowest for the analyzed substance. Establish the method range for atorvastatin and etoricoxib to include therapeutic plasma or serum levels along with the drug concentrations found in pharmaceutical versions. The method needs proper validation during this drug concentration range to enable precise measurements of all drug levels.(57)
7. **Robustness and Ruggedness**: A robust method demonstrates stability when operative parameters like temperature, pH or solvent show minor changes. The reliability of a method during testing by different analysts and equipment represents its ruggedness quality. The evaluation of both parameters occurs through purposeful modification of specific experimental conditions at which analysts determine the method's performance stability. Reliable analytics depends on procedures that perform reliably across changing environmental factors and equipment as well as analysts.(58)

International Guidelines for Method Validation (ICH, FDA)

The pharmaceutical industry follows validation guidelines for analytical methods through standards created by both the International Council for Harmonisation (ICH) and the U.S. Food and Drug Administration (FDA). The guidelines set by ICH and FDA establish methods for pharmaceutical analysis that maintain scientific validity and regulatory compliance while ensuring reproducible results.(59)

1. **ICH Guidelines**: The ICH organization harmonizes pharmaceutical regulatory standards between European, Japanese, and American regions through its document providing full guidance about analytical method validation. The ICH method validation guidelines exist in ICH Q2(R1) as it details the validation parameters of accuracy, precision, specificity, sensitivity and robustness. The pharmaceutical industry needs to perform validation of analytical methods for their desired use regardless of testing purposes including raw materials and finished products and in-process conditions per ICH Q2(R1). According to the guideline it is essential to show that a testing method can operate reliably as per regulatory quality control requirements during routine quality assessment.(59)
2. **FDA Guidelines**: The Food and Drug Administration's bioanalytical method validation guidelines match International Conference for Harmonisation standards while providing supplementary requirements specifically for bioanalytical testing. The FDA states that all assessment methods employed during clinical trials and bioequivalence

studies along with post-marketing surveillance need validation to confirm drug product consistency. The FDA demands thorough evaluation of analysis methods for their capability to determine drug levels in intricate biological specimens including plasma urine and serum. New drugs need regulatory approval through the submission of validated data according to the FDA guidance that focuses on method robustness testing through multiple operating conditions.(60)

According to regulatory requirements of FDA and ICH enforcing organizations must sustain documentation about verification tasks encompassing original data entries and mathematical computations together with written reports for audit purposes and inspection needs. Suited compliance with these guidelines makes certain analytical methods meet both scientific standards and requirements for drug development and quality control work.(61)

5. CHALLENGES IN SIMULTANEOUS ESTIMATION

The joint analytical quantification of atorvastatin and etoricoxib components requires specific solutions because of complex analytical difficulties. Multi-component systems along with solvent and matrix effects generate the main challenges during simultaneous estimation of multiple components. (62) Precise quantification of single or multiple drugs in pharmaceutical formulations and biological samples requires overcoming these analytical challenges because multiple drugs exist within the same formulation or sample.(63)

Interference Issues in Multi-component Systems

The main difficulty in performing simultaneous estimation involves managing the impact made by secondary substances contained within multiple component systems. The drug compounds found in pharmaceutical formulations or biological samples exist alongside excipients and metabolites and impurities because drugs normally appear without isolation from these substances.(64) The combination of substances produces misread and altered results through simultaneous absorption effects at the chosen wavelengths. The determination of similar drugs becomes challenging because their absorption peaks can be near identical or overlap one another particularly in cases involving tablet formulations and biological fluids. Such spectral similarities exist between atorvastatin and etoricoxib.(65) Different approaches exist to solve these multi-component system interferences. The method of A spectrum with overlapping bands makes the task of correctly determining single concentrations difficult in complex drug mixtures. The light-absorbing properties of pharmaceutical excipients such as fillers and binders and colorants create additional interference with target analytes because their wavelengths match excipients' wavelengths. (66) Derivative spectrophotometry serves as a popular technique which uses spectrum differentiation to split overlapping peaks in absorption bands. Derivative spectrophotometry improves analysis accuracy since it focuses on absorbance rate changes while disregarding absolute values. Multi-component systems can be processed through advanced analytical methods such as principal component analysis (PCA) and partial least squares (PLS) regression which separate data components even in cases of overlapping peaks.(67) Analyzing each compound through its distinctive spectral characteristics becomes possible when using advanced techniques even when additional compounds are present in the sample stream. Simultaneous estimation through multiple wavelength selection helps minimize spectral interference. (68)The selectivity improves while interference decreases because scientists can choose specific wavelengths either for individual component absorbance pattern distinction or for the maximum absorption of combined wavelengths. Method development requires deliberate optimization because it determines which wavelength combination successfully reduces interferences thus enabling accurate dual-assessment.(69)

Solvent and Matrix Effects

Simultaneous estimation faces a major challenge because solvent as well as matrix effects pose problems specifically when using UV-Vis spectrophotometry. The absorbance properties of an analyte are strongly influenced by selecting appropriate solutions for dissolving drug samples. (33) Various solvents interact with atorvastatin and etoricoxib molecules and other sample substances which changes their absorption spectra with wavelength effects or absorption intensity. A solvent's impact on an analyte will be particularly strong when the solvent molecules do not agree with the compound structure or when one spectrum overlaps with another.(70)

Solvent absorbance in the areas where atorvastatin or etoricoxib absorb in UV light will generate baseline distortions and measurement signal degradation. The absorbance from the solvent solution interferes with the accurate measurement of analyte signals because it hides their absorption features. (71)The selection of appropriate solvent constitutes a key factor to minimize variations that affect the analysis. A solvent which does not absorb UV radiation at the region of interest should be used for analysis. This solvent must dissolve atorvastatin and etoricoxib while avoiding structural changes to either compound. Then selection of solvents for UV-Vis analysis depends on the compounds' solubility characteristics and chemical properties since the most frequently used solvents consist of methanol, ethanol, acetonitrile, and phosphate buffers.(72)

Biological specimens such as plasma and serum and urine face critical matrix effects which become significant during analysis procedures. A biological matrix containing proteins together with salts and lipids along with other biological substances disrupts the reliable measurement of drug concentrations. The components in biological matrices trigger three types of effects that degrade the analyte absorption properties: light scattering alongside background absorbance and

chemical interactive processes. (73)The multiple components found in biological matrices interfere with researchers attempting to separate target compounds from other substances present in the mixture. Analysis of biological matrices proves challenging due to their exceptionally low analyte concentrations compared to pharmaceutical concentrations.(16)

The application of extraction methods such as SPE and LLE assists in extracting target substances from matrix compounds thereby decreasing the risk of interference. The combination of these techniques enhances measurement specificity by performing drug concentration along with rejecting potential interferences. The analysis of blank samples made up of pure matrix materials serves to detect any shifts or spectral disturbances which the matrix could create. The technique determines the baseline measurements to compensate for any possible matrix impacts so drug concentration quantification becomes possible.(74)

The use of internal standards stands as another method to handle matrix effects during analysis. Researchers add an internal standard containing a chemically corresponding compound to the analyte yet unpertaining to its measurement procedure. Analysts can account for variations induced by the matrix by adding a known amount of internal standard at the start of sample analysis to achieve improved measurement accuracy. (75)The internal standard serves as a quantitative control to compensate for matrix-related baseline alterations and intensity alterations which results in improved accuracy of the atorvastatin and etoricoxib quantification.(76)

6. RECENT ADVANCES AND INNOVATIONS

Recent years have brought numerous significant advances to UV-Vis spectrophotometry because pharmaceutical analysts require precise efficient analysis techniques with broader applicability. Researchers have established new advances for UV-Vis spectrophotometry to solve fundamental multiple components analysis challenges and boost sensitivity performance together with reduced interference. (77)Strategies using new approaches and techniques have enhanced the precision and reliability of UV-Vis spectrophotometry that is used to analyze complex mixtures of atorvastatin and etoricoxib.(78)

Novel Approaches in UV-Vis Spectrophotometry

1. **Derivative Spectrophotometry**: Derivative spectrophotometry represents an innovative UV-Vis spectrophotometry advancement because it successfully resolves overlapping peaks when analyzing multi-component mixtures. The procedure requires standard absorbance spectra differentiation to boost the distinct separation of individual components. This method reveals the change in absorbance through first or second derivatives which enhances peak separation between components even when the peaks are adjacent to each other. The utilization of derivative spectrophotometry enhances method sensitivity and specificity which enables better precision for determining both atorvastatin and etoricoxib concentrations particularly when they coexist in overlapping spectra.(79)
2. **Multivariate Calibration**: UV-Vis spectrophotometry has been improved by multivariate calibration approaches like Partial Least Squares (PLS) and Principal Component Regression (PCR) when analyzing multiple components. The analytical procedure determines multiple components through its ability to process complete spectral information rather than select specific wavelengths. These methods address spectral interferences while handling overlapping absorption bands because they extract significant details from the complete spectrum. The powerful calibration method known as multivariate performs well at determining compounds that overlap during absorption such as atorvastatin and etoricoxib. These methods enable precise drug quantification when dealing with sample interruptions caused by interfering components and excipients as well as other drugs in the system. They establish predictive systems for drug concentration analysis.(80)



Figure 2: The placement of this figure follows the "Multivariate Calibration" section because it explains how multivariate calibration methods (such as PLS or PCR) separate spectra from multi-component systems. The visual presentation demonstrates sophisticated analytical methods which permit separate quantitative measurements of atorvastatin and etoricoxib even though their spectra cross each other.

3. **Use of Chemometrics**: This implementation of mathematical and statistical analysis methods enables the study of chemical data which leads to powerful improvements of UV-Vis spectrophotometric analysis. Researchers use Cluster Analysis and Multivariate Analysis of Variance (MANOVA) to analyze diverse datasets for identifying patterns of interrelation between various measurement factors like drug concentration or solvent influence or interference effects. Applying chemometric techniques allows investigators to select optimal experimental parameters together with understanding data better while reducing human analysis-based mistakes which proves beneficial for multiple drug quantification in one sample.
4. **Microfluidic Devices and Lab-on-a-Chip Technology**: UV-Vis spectrophotometry stands out with the current innovation of combining microfluidic devices alongside LOC technologies. The technology executes precise measurements on tiny samples through a method that cuts both reagent usage and analytical periods. The system of microfluidics includes small channels and reaction chambers that combine to provide fast analyte mixing while separating and detecting these compounds. Such systems enhance the assessments delivered by UV-Vis spectrophotometry through their superior analytical capabilities and real-time operating potential. These innovations find their most useful application in clinical and point-of-care diagnostics because they provide crucial precise measurement of drug concentrations in quick time.(81)

New Techniques for Simultaneous Estimation

1. **Dual-Wavelength UV-Vis Spectrophotometry**: Simultaneous estimation obtains promising results through dual-wavelength UV-Vis spectrophotometry since measurements at different wavelengths detect maximum absorbance of each analyte independently from one another. This technique enables the simultaneous counting of two compounds without experiencing substantial disturbance from one another. The dual-wavelength UV-Vis spectrophotometric method enables identification of two specific wavelengths for atorvastatin and etoricoxib absorption because both drugs demonstrate intense separate peaks. Measuring absorbance values at the chosen wavelengths allows individual calculation of drug concentrations. Dual-wavelength spectrophotometry establishes a quick and affordable method that quantifies several compounds during the same measurement process. (82)
2. **Multi-Wavelength Spectrophotometry**: Simultaneous analysis can be achieved using multi-wavelength spectrophotometry by expanding dual-wavelength spectrometry principles. Multi-wavelength spectrophotometry uses multiple wavelength measurements to get an extensive set of data for analysis purposes. Multi-wavelength spectrophotometry remains a valuable tool when drugs with extensive separation of absorption peaks like atorvastatin and etoricoxib need to be analyzed simultaneously. Multiple chemometric data processing methods or multivariate calibration algorithms allow researchers to distinguish each component spectrum when spectral overlap occurs between different components.
3. **Fourier Transform UV-Vis (FT-UV-Vis) Spectroscopy**: The Fourier Transform (FT) technology has found its application in UV-Vis spectrophotometry after being originally developed for infrared (IR) and nuclear magnetic resonance (NMR) spectroscopy. Utilizing the FT-UV-Vis spectroscopic method delivers superior performance to conventional UV-Vis techniques due to speedier data collection and enhanced signal clarity and increased signal strength ratios. UV-Vis absorbance spectra are acquired as sequences of interferograms through FT-UV-Vis technology until Fourier transformations generate typical absorption spectra. FT-UV-Vis spectroscopy proves most beneficial for complicated sample solutions because it provides exceptionally sensitive detection that enables simultaneous identification of various components at low concentrations. (83)
4. **Surface Plasmon Resonance (SPR) Coupled with UV-Vis**: Surface plasmon resonance (SPR) technology utilizes innovative ways of combining with UV-Vis spectrophotometry. Researchers can utilize SPR as an optical technique because it precisely assesses refractive index changes near metallic surfaces to determine molecular binding events. By merging SPR technology with UV-Vis spectrophotometry the measurement sensitivity increases for simultaneous drug analysis involving atorvastatin and etoricoxib. The combined method has exceptional capability for detecting trace drug amounts in difficult sample matrices thus proving advantageous in bioanalytical work.
5. **Portable and Handheld UV-Vis Spectrometers**: Portable handheld UV-Vis spectrometers came into being thanks to technological progress for testing pharmaceutical samples in real time and on location. The miniature analytical instruments operate through field testing and quality control procedures with similar capabilities to laboratory equipment yet they exist in a mobile design. The ability to test drug concentrations in quick and precise ways using portable UV-Vis spectrometers makes them beneficial for examination procedures in distant locations together with medical facilities and production sites. (84)

7. APPLICATIONS IN PHARMACEUTICAL INDUSTRY

The pharmaceutical industry heavily relies on UV-Vis spectrophotometry as an important analytical technique because it provides multiple applications for quality control and routine testing and research purposes. The tool delivers swift exact nondestructive drug concentration assessments which demonstrates major importance for pharmaceutical quality control programs. The pharmaceutical sector utilizes UV-Vis spectrophotometry through three main applications that include quality control as well as routine testing alongside real-life case studies.

Quality Control and Routine Testing

1. **Assay of Active Pharmaceutical Ingredients (APIs)**: API quality control within pharmaceutical manufacturing requires assay tests as an essential measurement process. UV-Vis spectrophotometers help pharmaceutical industries determine active ingredient concentrations in both starting materials before manufacturing begins as well as finished products after production. The absorbance readings at assigned wavelengths allow manufacturers to verify medication amounts and verify if product requirements are achieved. The UV-Vis spectrophotometric method enables identification of correct medicine amounts and detection of storage and manufacturing degradation in atorvastatin and etoricoxib tablet formulations and suspensions. (85)
2. **Determination of Purity**: UV-Vis spectrophotometry serves as a standard tool in quality control applications where purity tests represent one of its primary uses. The analysis can detect degradation products as well as impurities that may compromise drug effectiveness because this technique monitors the therapeutic drug. UV-Vis spectrophotometry analyzes atorvastatin and etoricoxib spectra for any undesirable peaks because such patterns can reveal unwanted impurities consisting of degradation products and excipient contaminants. UV-Vis spectrophotometry enables drug purity checking through a simple procedure that does not require prolonged analytical methods such as chromatography. (18)
3. **Stability Studies**: The shelf life together with quality changes due to environmental elements such as light and temperature and humidity undergo rigorous stability testing for pharmaceutical products. The monitoring of drug concentration and purity in stability research relies heavily on UV-Vis spectrophotometry equipment. Scientists can measure atorvastatin and etoricoxib degradation through UV-Vis spectrophotometric methods although light exposure or heat affect their stability. The information obtained from these studies helps pharmaceutical manufacturers determine proper expiration periods through which their medications remain effective and safe until they expire.
4. **Dissolution Testing**: The quality assessment of oral drugs necessitates dissolution testing as an essential procedure. The assessment of dosage form drug release into a dissolution medium takes place under conditions which replicate gastrointestinal tract conditions. UV-Vis spectrophotometry serves to measure drug concentration changes that occur during the time span in dissolution medium. The specified time points during atorvastatin tablet dissolution enable researchers to monitor atorvastatin concentration in the solution for determining drug release characteristics. The data collected from the tests will confirm the drug's ability to fulfill its dissolution standards which guarantees effective drug distribution in patients. (86)
5. **Bioequivalence Testing**: Bioequivalence testing plays an essential role in regulatory approvals for generic drugs during their development process. Very often UV-Vis spectrophotometry serves to compare drug release patterns between generic versions and brand origin products. The bioavailability test confirms that the generic drug provides equivalent amounts of active ingredient to the bloodstream just as the original brand product. The direct and dependable evaluation of bioequivalence is possible through UV-Vis spectrophotometry by quantifying active ingredient concentrations in similar test conditions.
6. **Analysis of Excipients**: The excipients used with active pharmaceutical ingredients such as fillers and binders and stabilizers impact the quality standards of the finished product. The levels of excipients in formulations can be monitored for accuracy by using UV-Vis spectrophotometry to check both amount and composition. UV-Vis spectrophotometry enables excipient assessment to examine their impact on active pharmaceutical ingredients (APIs) including atorvastatin or etoricoxib to discover any probable influences on chemical stability or drug availability.(87)

8. CASE STUDIES AND REAL-WORLD APPLICATIONS

1. **Simultaneous Estimation of Atorvastatin and Etoricoxib in Tablet Formulation**: A practical study based on UV-Vis spectrophotometry demonstrates a dual-analysis process of atorvastatin and etoricoxib in pharmaceutical tablets. Medical practitioners commonly team these drugs together to treat patients with dual hyperlipidemia and inflammatory disorders of arthritis. An optimized UV-Vis spectrophotometric method estimates atorvastatin and etoricoxib quantities in one tablet simultaneously through direct measurements that eliminate time-consuming separation procedures and sample purification methods. A dual-wavelength UV-Vis spectrophotometric method optimized its wavelength selection to monitor atorvastatin at 246 nm and etoricoxib at 231 nm that allowed separate

detection of both drugs in mixture solutions. The methodology passed necessary validation tests for accuracy and precision in addition to checking specificity and robustness which qualified it for industrial pharmaceutical quality control applications.

2. **Monitoring Drug Stability in Injectable Formulations**: The pharmaceutical industry uses UV-Vis spectrophotometry to evaluate the stability of drugs present in injectable pharmaceutical products. UV-Vis spectrophotometry played an essential role in monitoring the stability behavior of intravenous (IV) formulations containing atorvastatin and etoricoxib. The method served to track drug concentration changes that occurred during distinct storage periods which included different light conditions and temperature settings. The research found appropriate storage conditions and formulated shelf life to maintain drug safety and effectiveness throughout the usage duration. The real-time measurements from UV-Vis spectrophotometry helped identify drug breakdown speed during which researchers could speed up their storage method development.(88)
3. **Pharmacokinetic Studies of Combination Therapies**: Academic investigations of drug behavioral patterns in human bodies depend on UV-Vis spectrophotometry techniques. The concentration evaluation of combination drugs atorvastatin and etoricoxib in biological fluids like plasma or serum happens through UV-Vis spectrophotometric analysis. The UV-Vis spectrophotometry method was employed to measure plasma concentrations of atorvastatin and etoricoxib in patients receiving double therapy through a clinical study. Laboratory research analyzing these studies provided fundamental knowledge about the drug pharmacokinetic profiles as well as their ADME attributes. This method enabled researchers to measure both drugs within one sample which improved analysis performance and decreased the required complex processes during large clinical trials.(89)
4. **Field Testing of Pharmaceuticals in Remote Areas**: Remote healthcare facilities nowadays deploy portable UV-Vis spectrophotometers to conduct field tests on pharmaceutical products because they lack laboratory resources. The assessment of antimalarial drug quality through UV-Vis spectrophotometry was carried out in sub-Saharan Africa while examining medications composed of multiple therapeutic elements. Drugs could be assessed for potency and purity by this field-based testing technology that analyzed drug samples right at the testing location. The same testing method should be applied to atorvastatin and etoricoxib medications in developing countries because it can determine substandard drug distribution while enhancing treatment results.(90)

9. CONCLUSION

The combination of atorvastatin and etoricoxib testing relies on UV-Vis spectrophotometry which provides efficient and cost-effective pharmaceutical analysis methods with high reliable outputs. Significant improvements occurred in sensitivity as well as accuracy and precision because derivative spectrophotometry and multivariate calibration were developed alongside microfluidic technology integration. Such advancements have improved the utility of complex multi-component system handling so researchers can address systematic limitations while performing analysis. Research on UV-Vis spectrophotometry in pharmaceutical quality control will evolve through enhancements to sensitivity and AI integration together with miniature point-of-care analytical devices to maximize instrument utility. The emphasis on sustainability and global harmonization techniques will ensure efficient environmental-friendly analytical methods that take effect in the future. UV-Vis spectrophotometry will serve as a critical element for pharmaceutical quality control as the industry continues to develop.

REFERENCES

[1] Davies JT, Delfino SF, Feinberg CE, Johnson MF, Nappi VL, Olinger JT, et al. Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. Lipid Insights. 2016;9:13-29.

[2] Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PHR, Newton RS, et al. Inhibition of HMG-CoA Reductase by Atorvastatin Decreases Both VLDL and LDL Apolipoprotein B Production in Miniature Pigs. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17(11):2589-600.

[3] Martina SD, Vesta KS, Ripley TL. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005;39(5):854-62.

[4] Abdelwahab NS, El-Zeiny BA, Tohamy SI. Two spectrophotometric methods for simultaneous determination of some antihyperlipidemic drugs. Journal of Pharmaceutical Analysis. 2012;2(4):279-84.

[5] Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1-10.

[6] Alffenaar JC, Heysell SK, Mpagama SG. Therapeutic Drug Monitoring: The Need for Practical Guidance. Clin Infect Dis. 2019;68(6):1065-6.

[7] Buschmann H, Handler N, Holzgrabe U. The quality of drugs and drug products – Always guaranteed? Journal of Pharmaceutical and Biomedical Analysis. 2024;239:115880.

[8] Pearson RA, Wicha SG, Okour M. Drug Combination Modeling: Methods and Applications in Drug

Development. J Clin Pharmacol. 2023;63(2):151-65.

[9] Sharma S, Sharma MC. Development and validation of new analytical methods for simultaneous estimation of Drotaverine hydrochloride in combination with Omeprazole in a pharmaceutical dosage form. Arabian Journal of Chemistry. 2017;10:S397-S403.

[10] El-Malla S, Kamal A, Hammad S. A review on UV spectrophotometric methods for simultaneous multicomponent analysis. European Journal of Pharmaceutical and Medical Research (EJPMR). 2016;3:348-60.

[11] Chang SM, Matchar DB, Smetana GW, Umscheid CA, Gray R, Torchia M. Methods guide for medical test reviews. Rockville: Agency for Healthcare Research and Quality. 2012.

[12] Payne RA, Avery AJ. Polypharmacy: one of the greatest prescribing challenges in general practice. Br J Gen Pract. 2011;61(583):83-4.

[13] Hammond JP. Chapter 11 - The Use of Spectrophotometry in the Pharmaceutical Industry. In: Germer TA, Zwinkels JC, Tsai BK, editors. Experimental Methods in the Physical Sciences. 46: Academic Press; 2014. p. 409-56.

[14] Derayea SM, Madian H, Samir E, Badr-eldin KM. Ecofriendly and smart spectrophotometric approaches for synchronized analysis of two antipsychotic drugs, fluoxetine and olanzapine: application to combined tablet dosages with assessment of method greenness. BMC Chemistry. 2025;19(1):38.

[15] Loos G, Van Schepdael A, Cabooter D. Quantitative mass spectrometry methods for pharmaceutical analysis. Philos Trans A Math Phys Eng Sci. 2016;374(2079).

[16] Panuwet P, Hunter RE, Jr., D'Souza PE, Chen X, Radford SA, Cohen JR, et al. Biological Matrix Effects in Quantitative Tandem Mass Spectrometry-Based Analytical Methods: Advancing Biomonitoring. Crit Rev Anal Chem. 2016;46(2):93-105.

[17] Wang L, Yuan L, Pan L, Ji QC. Chapter 24 - Bioanalysis of biological matrix samples using liquid chromatography–tandem mass spectrometry detection. In: Riley CM, Rosanske TW, Reid G, editors. Specification of Drug Substances and Products (Second Edition): Elsevier; 2020. p. 641-59.

[18] De Caro C, Claudia H. UV/Vis Spectrophotometry - Fundamentals and Applications2025.

[19] Mandru A, Mane J, Mandapati R. A Review on UV-visible spectroscopy. Journal of Pharma Insights and Research. 2023;1(2):091-6.

[20] Sudharshan N, Swetha V. UV-VISIBLE SPECTROSCOPY: A COMPREHENSIVE REVIEW ON INSTRUMENTATION. World J Pharm Res. 2023;12(19):1342-63.

[21] Primer A. Fundamentals of UV-visible spectroscopy. Copyright Hewlett-Packard Company, Hewlett-Packard publication. 1996(12-5965).

[22] Sinha S, Jeyaseelan C, Singh G, Munjal T, Paul D. Chapter 8 - Spectroscopy—Principle, types, and applications. In: Bhatt AK, Bhatia RK, Bhalla TC, editors. Basic Biotechniques for Bioprocess and Bioentrepreneurship: Academic Press; 2023. p. 145-64.

[23] Østergaard J. UV/Vis Spectrophotometry and UV Imaging. In: Müllertz A, Perrie Y, Rades T, editors. Analytical Techniques in the Pharmaceutical Sciences. New York, NY: Springer New York; 2016. p. 3-27.

[24] Sánchez Rojas F, Cano Pavón JM. SPECTROPHOTOMETRY | Biochemical Applications. In: Worsfold P, Townshend A, Poole C, editors. Encyclopedia of Analytical Science (Second Edition). Oxford: Elsevier; 2005. p. 366-72.

[25] Burgess C. Chapter 2 - The basis for good spectrophotometric UV–visible measurements. In: Thomas O, Burgess C, editors. UV-Visible Spectrophotometry of Waters and Soils (Third Edition): Elsevier; 2022. p. 25-58.

[26] Brown B, Ward A, Fazili Z, Østergaard J, Asare-Addo K. Application of UV dissolution imaging to pharmaceutical systems. Advanced Drug Delivery Reviews. 2021;177:113949.

[27] L.C. Passos M, M.F.S. Saraiva ML. Detection in UV-visible spectrophotometry: Detectors, detection systems, and detection strategies. Measurement. 2019;135:896-904.

[28] Pandey S, Pandey P, Tiwari G, Tiwari R. Bioanalysis in drug discovery and development. Pharm Methods. 2010;1(1):14-24.

[29] Shinde KP, Rajmane AD. A review UV method development and validation. Asian Journal of Pharmaceutical Analysis. 2023;13(2):122-30.

[30] 30Mayuri D, Ravindranath S. Analytical Method Development and Validation: A Review. Journal of Drug

Delivery & Therapeutics. 2019;9(3).

[31] Patil M, Patil R, Chalikwar S, Surana S, Firke S. Analytical method development and validation: A review. International Journal of Pharmaceutical and Biological Science Archive. 2019;7(3).

[32] Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703-20.

[33] Cerdà V, Phansi P, Ferreira S. From mono- to multicomponent methods in UV-VIS spectrophotometric and fluorimetric quantitative analysis – A review. TrAC Trends in Analytical Chemistry. 2022;157:116772.

[34] Wang T, Zheng Y, Xu L, Yun Y-H. Comprehensive comparison on different wavelength selection methods using several near-infrared spectral datasets with different dimensionalities. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2025;331:125767.

[35] Alruwaili NK. Analytical Quality by Design Approach of Reverse-Phase High-Performance Liquid Chromatography of Atorvastatin: Method Development, Optimization, Validation, and the Stability-Indicated Method. Int J Anal Chem. 2021;2021:8833900.

[36] Kolář P, Shen J-W, Tsuboi A, Ishikawa T. Solvent selection for pharmaceuticals. Fluid Phase Equilibria. 2002;194-197:771-82.

[37] Salehi N, Kuminek G, Al-Gousous J, Sperry DC, Greenwood DE, Waltz NM, et al. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis. Mol Pharm. 2021;18(9):3326-41.

[38] Stielow M, Witczyńska A, Kubryń N, Fijałkowski Ł, Nowaczyk J, Nowaczyk A. The Bioavailability of Drugs-The Current State of Knowledge. Molecules. 2023;28(24).

[39] Kanu AB. Recent developments in sample preparation techniques combined with high-performance liquid chromatography: A critical review. Journal of Chromatography A. 2021;1654:462444.

[40] Yarborough V, Haskin J, Lambdin W. Temperature dependence of absorbance in ultraviolet spectra of organic molecules. Analytical Chemistry. 1954;26(10):1576-8.

[41] Lotfy HM, El-Hanboushy S, Fayez YM, Abdelkawy M. Spectral analysis of overlapped absorption bands of binary mixtures—an application on combination of pseudoephedrine sulphate and loratadine mixture. Future Journal of Pharmaceutical Sciences. 2019;5:1-14.

[42] Lotfy HM, Saleh SS, Hassan NY, Salem H. Novel two wavelength spectrophotometric methods for simultaneous determination of binary mixtures with severely overlapping spectra. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2015;136:1786-96.

[43] Chen HY, Chen C. Evaluation of Calibration Equations by Using Regression Analysis: An Example of Chemical Analysis. Sensors (Basel). 2022;22(2).

[44] Bhavyasri K, Surekha T, Rambabu D. Bioanalytical Method Development and Validation of Atorvastatin in Human Plasma by Using UV-Visibile Spectrophotometry. Journal of Pharmaceutical Sciences and Research. 2019;11(6):2243-6.

[45] Tan A, Awaiye K, Jose B, Joshi P, Trabelsi F. Comparison of different linear calibration approaches for LC–MS bioanalysis. Journal of Chromatography B. 2012;911:192-202.

[46] Stalikas C, Sakkas V. From a glimpse into the key aspects of calibration and correlation to their practical considerations in chemical analysis. Mikrochim Acta. 2024;191(2):81.

[47] Araujo P. Key aspects of analytical method validation and linearity evaluation. Journal of Chromatography B. 2009;877(23):2224-34.

[48] Chavan S, Desai D. Analytical method validation: A brief review. World Journal of Advanced Research and Reviews. 2022;16:389-402.

[49] Chesher D. Evaluating assay precision. Clin Biochem Rev. 2008;29 Suppl 1(Suppl 1):S23-6.

[50] Soori H. Precision, Validity, and Repeatability of Measurements and Diagnostic Tests. In: Soori H, editor. Errors in Medical Science Investigations. Singapore: Springer Nature Singapore; 2024. p. 73-96.

[51] Pum J. Chapter Six - A practical guide to validation and verification of analytical methods in the clinical laboratory. In: Makowski GS, editor. Advances in Clinical Chemistry. 90: Elsevier; 2019. p. 215-81.

[52] Zhou W, Li Z, Bai L, Fu X, Qu B, Miao M. Basics of Measurement and Test Precision and the Effect of Measurement Methods on Measurement Precision. In: Zhou W, Li Z, Bai L, Fu X, Qu B, Miao M, editors. The Border Effect in High-Precision Measurement. Singapore: Springer Nature Singapore; 2023. p. 19-89.

[53] Alhazmi HA, Alnami AM, Arishi MAA, Alameer RK, Al Bratty M, Rehman ZU, et al. A Fast and Validated

Reversed-Phase HPLC Method for Simultaneous Determination of Simvastatin, Atorvastatin, Telmisartan and Irbesartan in Bulk Drugs and Tablet Formulations. Sci Pharm. 2017;86(1).

[54] Momenbeitollahi N, Cloet T, Li H. Pushing the detection limits: strategies towards highly sensitive optical-based protein detection. Anal Bioanal Chem. 2021;413(24):5995-6011.

[55] Epshtein N. VALIDATION OF ANALYTICAL PROCEDURES: GRAPHIC AND CALCULATED CRITERIA FOR ASSESSMENT OF METHODS LINEARITY IN PRACTICE. 2019;8:122-30.

[56] Gustavo González A, Ángeles Herrador M. A practical guide to analytical method validation, including measurement uncertainty and accuracy profiles. TrAC Trends in Analytical Chemistry. 2007;26(3):227-38.

[57] Abdel GMT, El-Masry MI. Verification of quantitative analytical methods in medical laboratories. J Med Biochem. 2021;40(3):225-36.

[58] Vander Heyden Y, Nijhuis A, Smeyers-Verbeke J, Vandeginste BGM, Massart DL. Guidance for robustness/ruggedness tests in method validation. Journal of Pharmaceutical and Biomedical Analysis. 2001;24(5):723-53.

[59] Bhavna, Ojha A, Bhargava S. Chapter 3 - International Council for Harmonisation (ICH) guidelines. In: Ali J, Baboota S, editors. Regulatory Affairs in the Pharmaceutical Industry: Academic Press; 2022. p. 47-74.

[60] Kadian N, Raju KSR, Rashid M, Malik MY, Taneja I, Wahajuddin M. Comparative assessment of bioanalytical method validation guidelines for pharmaceutical industry. Journal of Pharmaceutical and Biomedical Analysis. 2016;126:83-97.

[61] Bode G. Regulatory Guidance: ICH, EMA, FDA. In: Hock FJ, Gralinski MR, editors. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Cham: Springer International Publishing; 2019. p. 1-54.

[62] Crevar-Sakač M, Vujić Z, Brborić J, Kuntić V, Uskoković-Marković S. An improved HPLC method with the aid of a chemometric protocol: simultaneous determination of atorvastatin and its metabolites in plasma. Molecules. 2013;18(3):2469-82.

[63] Abhinandana P. A review of various analytical methods on Atrovastatin. 2013.

[64] Badyal P, Sharma C, Kaur N, Shankar R, Pandey A, Rawal R. Analytical Techniques in Simultaneous Estimation: An Overview. Austin Journal of Analytical and Pharmaceutical Chemistry. 2015;2:1037.

[65] Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nature Reviews Drug Discovery. 2009;8(2):111-28.

[66] Parmar A, Sharma S. Derivative UV-vis absorption spectra as an invigorated spectrophotometric method for spectral resolution and quantitative analysis: Theoretical aspects and analytical applications: A review. TrAC Trends in Analytical Chemistry. 2016;77:44-53.

[67] Bosch Ojeda C, Sanchez Rojas F. Recent applications in derivative ultraviolet/visible absorption spectrophotometry: 2009–2011: A review. Microchemical Journal. 2013;106:1-16.

[68] Ortiz Ortega E, Hosseinian H, Rosales López MJ, Rodríguez Vera A, Hosseini S. Characterization Techniques for Chemical and Structural Analyses. In: Ortiz Ortega E, Hosseinian H, Aguilar Meza IB, Rosales López MJ, Rodríguez Vera A, Hosseini S, editors. Material Characterization Techniques and Applications. Singapore: Springer Singapore; 2022. p. 93-152.

[69] Persson B-A, Vessman J. The use of selectivity in analytical chemistry – some considerations. TrAC Trends in Analytical Chemistry. 2001;20(10):526-32.

[70] Saiyed N, Nathani C, Patel S, Saduwala Z, Ugle V, Shah C, et al. SOLUBILITY ENHANCEMENT OF ATORVASTATIN BY DIFFERENT SOLUBILITY ENHANCEMENT TECHNIQUES -A COMPARISION STUDY. 2023;14:39-54.

[71] Shamsuddin, Fazil M, Ansari SH, Ali J. Atorvastatin solid dispersion for bioavailability enhancement. J Adv Pharm Technol Res. 2016;7(1):22-6.

[72] Shaker MA, Elbadawy HM, Shaker MA. Improved solubility, dissolution, and oral bioavailability for atorvastatin-Pluronic® solid dispersions. Int J Pharm. 2020;574:118891.

[73] Rudrapal M, Kothawade AP, Ezzat SM, Egbuna C. Chapter 1 - Bioanalysis: methods, techniques, and applications. In: Egbuna C, Patrick-Iwuanyanwu KC, Shah MA, Ifemeje JC, Rasul A, editors. Analytical Techniques in Biosciences: Academic Press; 2022. p. 1-24.

[74] Badawy MEI, El-Nouby MAM, Kimani PK, Lim LW, Rabea EI. A review of the modern principles and applications of solid-phase extraction techniques in chromatographic analysis. Anal Sci. 2022;38(12):1457-87.

[75] Hewavitharana AK, Abu Kassim NS, Shaw PN. Standard addition with internal standardisation as an alternative

to using stable isotope labelled internal standards to correct for matrix effects-Comparison and validation using liquid chromatography-tandem mass spectrometric assay of vitamin D. J Chromatogr A. 2018;1553:101-7.

[76] Cheng WL, Markus C, Lim CY, Tan RZ, Sethi SK, Loh TP. Calibration Practices in Clinical Mass Spectrometry: Review and Recommendations. Ann Lab Med. 2023;43(1):5-18.

[77] Ríos-Reina R, Azcarate SM. How Chemometrics Revives the UV-Vis Spectroscopy Applications as an Analytical Sensor for Spectralprint (Nontargeted) Analysis. Chemosensors. 2023;11(1):8.

[78] Antony A, Mitra J. Refractive index-assisted UV/Vis spectrophotometry to overcome spectral interference by impurities. Analytica Chimica Acta. 2021;1149:238186.

[79] Redasani V, Patel P, Marathe D, Chaudhari S, Shirkhedkar A, Surana S. A review on derivative uv-spectrophotometry analysis of drugs in pharmaceutical formulations and biological samples review. Journal of the Chilean Chemical Society. 2018;63:4126-34.

[80] Sowjanya G, S G, Almas S. DERIVATIVE UV SPECTROSCOPIC APPROACHES IN MULTICOMPONENT ANALYSIS–A REVIEW. International Journal of Pharmacy and Pharmaceutical Sciences. 2018:1-11.

[81] Tarapoulouzi M, Mironescu M, Drouza C, Mironescu ID, Agriopoulou S. Insight into the Recent Application of Chemometrics in Quality Analysis and Characterization of Bee Honey during Processing and Storage. Foods. 2023;12(3):473.

[82] Mukherjee P, Chakraborty D, Chakraborty P, Shrestha B, Bhuyan N. DIFFERENT ULTRAVIOLET SPECTROSCOPIC METHODS: A RETROSPECTIVE STUDY ON ITS APPLICATION FROM THE VIEWPOINT OF ANALYTICAL CHEMISTRY. Asian Journal of Pharmaceutical and Clinical Research. 2021:1-11.

[83] Gupta RS, Tiwari A, Patel SK, Karthikeyan C, Gupta DK, Soni P, et al. Development and validation of a UV spectrophotometric method for simultaneous estimation of teneligliptin hydrobromide hydrate and pioglitazone hydrochloride in pharmaceutical dosage form. Future Journal of Pharmaceutical Sciences. 2024;10(1):172.

[84] Vyas AJ, Desai DU, Patel A, Patel A, Shah S, Sheth D. A Brief Review on Dual Wavelength Spectrophotometry: The Simultaneous Estimation Method and its Application. Asian Journal of Pharmaceutical Analysis. 2024;14(3):166-74.

[85] Nurani L, Ariani C, Irnawati I, Putri A, Windarsih A, Guntarti A, et al. Chemometrics-Assisted UV-Vis Spectrophotometry for Quality Control of Pharmaceuticals: A Review. Indonesian Journal of Chemistry. 2023;23:542.

[86] Bajaj S, Singla D, Sakhuja N. Stability Testing of Pharmaceutical Products. Journal of Applied Pharmaceutical Science. 2012;2:129-38.

[87] Tembhare E, Gupta K, Umekar M. An Approach to Drug Stability Studies and Shelf-life Determination. Archives of Current Research International. 2019:1-20.

[88] Singh S, Mishra A, Verma A, Ghosh AK, Mishra AK. A simple Ultraviolet spectrophotometric method for the determination of etoricoxib in dosage formulations. J Adv Pharm Technol Res. 2012;3(4):237-40.

[89] Manideep G, Shane J, Pai K, Krishna M. Development and Validation of A UV Spectroscopic Method to Estimate Etoricoxib in Bulk and Tablet Formulation. Research Journal of Pharmacy and Technology. 2018;11:758.

[90] Kondawar M, D B, Maniyar M, hirve r. Spectrophotometric method for Simultaneous estimation of Atorvastatin Calcium & Fenofibrate in tablet Dosage Form. International Journal of Drug Development & Research. 2013;5:1-5.